Harnessing the predictive power of blood-based miRNAs

Company

Hummingbird is harnessing the predictive power of blood-borne miRNAs to provide insights into human health and disease. Analysis of miRNAs with Hummingbird’s platform holds the potential for early disease detection, disease-specific prognostics, treatment response prediction, and the development of patient-centric therapies. 

The privately held company is based in Heidelberg, Germany.

Developing novel miRNA diagnostics to improve human health

People

Our leadership

Management
Tobias Sikosek
PhD
Director Data Science
Kaja Tikk
PhD
Director Clinical & Regulatory Affairs
Jochen Kohlhaas
Founder & CEO
Bruno Steinkraus
PhD
CSO
Rastislav Horos
DVM PhD
VP Technology
Timothy Rajakumar
MD PhD
Director Medical
Board
Karoly Nikolich
Co-Founder & Board Member
Scott Gazelle
Chairman
Bernd Seibel
Vice Chairman
Tom Miller
Board Member
Hummingbird_Team.jpg

We are Hummingbird Diagnostics

Hummingbird’s dedicated and experienced team is committed to delivering results for patients.

We have developed best-in-class expertise in processing and analyzing blood-borne miRNAs, evaluating the immune system‘s response to disease with a proven track record in molecular diagnostics, clinical laboratory sciences, computational biology as well as in statistical machine learning and artificial intelligence.

a team of skilled and motivated scientists, physicians, engineers and professionals

Join Us

Our success rests upon a strong team!

Currently, there are no positions available.